Weight regain after discontinuation of GLP-1 class medications is well-documented the STEP 1 extension trial showed that most weight lost on semaglutide was regained within a year of stopping treatment
Foundayo (Orforglipron) Developed by Eli Lilly, Foundayo is an oral, non-peptide GLP-1 receptor agonist that has generated considerable excitement because it offers weight loss approaching that seen with injectable medications while avoiding injections altogether
Advantage : Neither (tie) Weight Loss Efficacy# Orforglipron : ATTAIN-1 demonstrated 12.4% mean weight loss at 36 mg over 72 weeks (efficacy estimand)
is supported by NIH research grants OT2HL161847, OT2OD032581, U24TR001608 and CDC project numbers 75D301-21-P-12254 and 75D301-23-C-18264
I look forward to helping you navigate your PCOS journey Before & Afters From Real Women with PCOS in Texas PCOS Weight Loss Dallas, TX Symptoms Obesity Hirsutism Acne and Skin Care PCOS Treatment Details The patient has lost 40 lbs in 8 months using a combination of semaglutide, diet, exercise, and hormone balancing
